导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.85% | 3521/4773 |
| 近一周 | -1.24% | 2792/5491 |
| 近一月 | 1.04% | 482/5408 |
| 近一季 | 3.64% | 594/5202 |
| 近半年 | -6.10% | 2885/4919 |
| 近一年 | -4.99% | 3148/4356 |
| 近两年 | 21.21% | 2597/2950 |
| 近三年 | 10.57% | 1689/2241 |
| 成立以来 | 184.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.08% 3759/4961 |
-7.98% 3821/5312 |
- - |
- - |
| 2025 | 7.53% 2922/4813 |
-1.35% 2646/3635 |
3.35% 1039/4076 |
1.61% 3874/4524 |
3.81% 618/4813 |
| 2024 | 21.07% 423/3463 |
4.20% 474/2808 |
4.05% 234/3014 |
13.94% 2071/3129 |
-2.00% 1921/3463 |
| 2023 | -8.36% 1006/2656 |
2.22% 1403/2280 |
-0.54% 389/2385 |
-1.69% 566/2515 |
-8.32% 2279/2655 |
| 2022 | -10.13% 199/2207 |
-6.50% 217/1919 |
2.64% 1276/2016 |
-10.48% 413/2113 |
4.61% 530/2208 |
| 2021 | 3.34% 615/1822 |
1.85% 239/1255 |
0.67% 1086/1330 |
-1.62% 535/1466 |
2.45% 594/1822 |
| 2020 | 23.57% 650/1250 |
-9.94% 732/1028 |
7.75% 835/1067 |
15.69% 201/1164 |
10.07% 617/1184 |
| 2019 | 34.96% 387/1092 |
22.59% 572/754 |
2.02% 102/804 |
0.99% 438/850 |
6.85% 532/918 |
| 2018 | -16.28% 106/834 |
- - |
- - |
- - |
-11.53% 311/691 |
| 2017 | 26.39% 102/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.92% 166/605 |
- - |
- - |
- - |
- - |
| 2015 | 2.36% 238/575 |
- - |
- - |
- - |
- - |
| 2014 | 60.59% 33/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.60% 127/186 |
- - |
- - |
- - |
- - |
| 2012 | 14.21% 17/140 |
- - |
- - |
- - |
- - |
| 2011 | -17.57% 16/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 建信上证社会责任ETF联接 VS. 长安沪深300非周期A(740101) |